CareFirst BlueCross/Blue Shield to Cover Vermillion's OVA1 | GenomeWeb

NEW YORK (GenomeWeb) – Vermillion said today that CareFirst Blue Cross/Blue Shield has begun covering the company's OVA1 ovarian cancer test.

According to Vermillion, CareFirst is the largest insurer in Maryland, covering 3.4 million people, representing more than 40 percent of the state's population.

With the announcement, Vermillion now has commercial coverage for OVA1 for more than 16 million lives. The company received another positive coverage decision for the test in April from Blue Cross/Blue Shield of Michigan.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.